TransMedics Group Inc. (TMDX)
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
TransMedics Group NASDAQ: TMDX outlined its growth strategy at Canaccord Genuity's 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation.
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract
TMDX's Q2 revenue beat and raised outlook are overshadowed by earnings miss, declining margins and sharply higher operating costs.
TransMedics Group, Inc. (TMDX) Q2 2026 Earnings Call Transcript
TransMedics Group, Inc. (TMDX) Q2 2026 Earnings Call Transcript
TransMedics Group Q2 Earnings Call Highlights
TransMedics Group NASDAQ: TMDX reported record second-quarter revenue as growth in liver procedures, clinical services and transplant logistics offset increased spending on product development, international expansion and infrastructure.
TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TransMedics (TMDX) Q2 Earnings Lag Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.92 per share a year ago.
Analysts Estimate TransMedics (TMDX) to Report a Decline in Earnings: What to Look Out for
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransMedics Completes PAD Aviation Investment to Expand in Europe
TMDX's PAD Aviation investment expands its OCS model into Europe, aiming to boost organ logistics, utilization and adoption.
Strata Critical Medical: A Better Alternative To TransMedics In Organ Transplant Logistics
Strata Critical Medical is rated a buy, driven by expanding market share, operational efficiencies, and a comprehensive suite of transplant logistics and clinical services. SRTA's asset-light-to-moderate model, strategic acquisitions, and focus on NRP technology position it to benefit from industry consolidation and secular tailwinds. Gross margin improvement is a key near-term catalyst, with management incentivized to reach 25% margins by 2027; Q1 2026 gross margin reached 21%.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.
